Comparative Pharmacology
Head-to-head clinical analysis: ELIXICON versus QUIBRON T.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ELIXICON versus QUIBRON T.
ELIXICON vs QUIBRON-T
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Theophylline is a xanthine derivative that inhibits phosphodiesterase, leading to increased intracellular cyclic AMP levels. It also acts as a nonselective adenosine receptor antagonist, resulting in bronchodilation and anti-inflammatory effects.
Quibron-T (theophylline) inhibits phosphodiesterase, increasing intracellular cAMP in airway smooth muscle and inflammatory cells, leading to bronchodilation and anti-inflammatory effects. It also antagonizes adenosine receptors and enhances respiratory drive.
400 mg orally every 6 hours or 600 mg orally every 8 hours; extended-release: 600-1200 mg orally every 12 hours.
Oral: 200-400 mg every 6-8 hours; sustained-release: 200-600 mg every 12 hours.
None Documented
None Documented
Terminal elimination half-life: 4-6 hours in adults; 3-4 hours in children; prolonged in hepatic impairment or congestive heart failure. Context: dosing interval adjustment required in these conditions.
Terminal elimination half-life: 7-9 hours in nonsmoking adults; prolonged in hepatic cirrhosis (up to 30 hours) or heart failure; shorter in smokers (4-5 hours) due to enzyme induction.
Renal: 50% unchanged; hepatic metabolism to 3-methylxanthine, theophylline, etc. Biliary/fecal: minimal.
Renal: 70% as metabolites (1,3-dimethyluric acid, 3-methylxanthine, and 1-methyluric acid) and 10% as unchanged drug in adults; biliary/fecal: minimal, <5%.
Category C
Category C
Xanthine Bronchodilator
Xanthine Bronchodilator